Tildrakizumab for Plaque Psoriasis

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Plaque PsoriasisTildrakizumab - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial looks at whether a drug called Tildrakizumab can help treat psoriasis by reducing the activity of a protein called IL-23.

Eligible Conditions
  • Plaque Psoriasis

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: baseline and 3 months

baseline and 3 months
Change in Psoriasis Area and Severity Index (PASI) Score from Baseline to 3 months

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Tildrakizumab treatment
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Tildrakizumab · No Placebo Group · Phase 4

Tildrakizumab treatment
Biological
Experimental Group · 1 Intervention: Tildrakizumab · Intervention Types: Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tildrakizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and 3 months

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,283 Previous Clinical Trials
11,577,734 Total Patients Enrolled
Sun Pharmaceutical Industries LimitedIndustry Sponsor
59 Previous Clinical Trials
13,463 Total Patients Enrolled
Raymond Cho, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
10 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have psoriasis or atypical psoriasis.